Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
Authors:
- Kennedy R LeesKLKennedy R Lees
- Kjell AsplundKAKjell Asplund
- Antonio CaroleiACAntonio Carolei
- Stephen M DavisSDStephen M Davis
- Hans-Christoph DienerHDHans-Christoph Diener
- Markku KasteMKMarkku Kaste
- Jean-Marc OrgogozoJOJean-Marc Orgogozo
- John WhiteheadJWJohn Whitehead
- 1 June 2000
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 355 (9219) , 1949-1954
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Phase II Studies of the Glycine Antagonist GV150526 in Acute StrokeStroke, 2000
- Selfotel in Acute Ischemic StrokeStroke, 2000
- Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug DevelopmentStroke, 1999
- Clomethiazole Acute Stroke Study (CLASS)Stroke, 1999
- Identification and pharmacological characterization of GV150526, a novel glycine antagonist as potent neuroprotective agentDrugs of the Future, 1998
- Lubeluzole Treatment of Acute Ischemic StrokeStroke, 1997
- Use of a Global Test for Multiple Outcomes in Stroke Trials With Application to the National Institute of Neurological Disorders and Stroke t-PA Stroke TrialStroke, 1996
- Application of Sequential Methods to a Phase III Clinical Trial in StrokeDrug Information Journal, 1993
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988